Immune response modifiers - Mode of action

Experimental Dermatology

Volumn 15, Issue 5, 2006, Pages 331-341

  Schiller, Meinhard ^a,d   Metze, Dieter ^a   Luger, Thomas A ^a   Grabbe, Stephan ^b   Gunzer, Matthias ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Imiquimod; Immunomodulation; Interleukin 1; NF B; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; RESIQUIMOD; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ALLERGIC ASTHMA; ANTIGEN PRESENTATION; ATOPIC DERMATITIS; B LYMPHOCYTE; BIOACCUMULATION; CANCER IMMUNOTHERAPY; CELL DEATH; CELL MIGRATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DERMIS; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; GENETIC CONSERVATION; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; LANGERHANS CELL; LYMPHATIC DRAINAGE; MACROPHAGE; MICROGLIA; MICROORGANISM; NONHUMAN; PATHOGENESIS; REVIEW; SKIN CANCER; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS INFECTION; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; LYMPHOCYTE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; DENDRITIC CELLS; HUMANS; IMMUNITY, NATURAL; KERATINOCYTES; LYMPHOCYTES; MICROGLIA; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; SKIN; TOLL-LIKE RECEPTORS;

EID: 33745266148     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2006.00414.x     Document Type: Review

References (89)

1. Krogsgaard M, Davis M M. How T cells 'see'antigen. Nat Immunol 2005: 6: 239-245.
2. Donnarumma G, Paoletti I, Buommino E, Tufano M A, Baroni A. α-MSH reduces the internalization of Staphylococcus aureus and down-regulates HSP 70, integrins and cytokine expression in human keratinocyte cell lines. Exp Dermatol 2004: 13: 748-754.
3. Maurer M, Metz M. The status quo and quo vadis of mast cells. Exp Dermatol 2005: 14: 923-929.
4. Elias P M, Choi E H. Interactions among stratum corneum defensive functions. Exp Dermatol 2005: 14: 719-726.
5. Janeway C A Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002: 20: 197-216.
6. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998: 134: 25-30.
7. Beutner K R, Geisse J K, Helman D, Fox T L, Ginkel A, Owens M L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999: 41: 1002-1007.
8. Hashimoto C, Hudson K L, Anderson K V. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988: 52: 269-279.
9. Lemaitre B, Nicolas E, Michaut L, Reichhart J M, Hoffmann J A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996: 86: 973-983.
10. Medzhitov R, Preston-Hurlburt P, Kopp E et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998: 2: 253-258.
11. Heil F, Ahmad-Nejad P, Hemmi H et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003: 33: 2907-2987.
12. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004: 5: 190-198.
13. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel D V. TRAF6 is a signal transducer for interleukin-1. Nature 1996: 383: 443-446.
14. Courtois G. NF-κB in skin homeostasis. Exp Dermatol 2005: 14: 781-782.
15. Weil R, Israel A. T-cell-receptor- and B-cell-receptor-mediated activation of NF-kappaB in lymphocytes. Curr Opin Immunol 2004: 16: 374-387.
16. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999: 11: 115-122.
17. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001: 166: 5688-5694.
18. Kobayashi K, Hernandez L D, Galan J E, Janeway C A Jr, Medzhitov R, Flavell R A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002: 110: 191-202.
19. Kinjyo I, Hanada T, Inagaki-Ohara K et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002: 17: 583-591.
20. Ilangumaran S, Ramanathan S, Rottapel R. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 2004: 16: 351-365.
21. Yoshimura A, Ohishi H M, Aki D, Hanada T. Regulation of TLR signaling and inflammation by SOCS family proteins. J Leukoc Biol 2004: 75: 422-427.
22. Harrison C J, Jenski L, Voychehovski T, Bernstein D I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988: 10: 209-223.
23. Harrison C J, Miller R L, Bernstein D I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994: 38: 2059-2064.
24. Chen M, Griffith B P, Lucia H L, Hsiung G D. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother 1988: 32: 678-683.
25. Steinmann A, Funk J O, Schuler G, von Den D P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000: 43: 555-556.
26. Sidky Y A, Borden E C, Weeks C E, Reiter M J, Hatcher J F, Bryan G T. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992: 52: 3528-3533.
27. Naylor M. Imiquimod and superficial skin cancers. J Drugs Dermatol 2005: 4: 598-606.
28. McInturff J E, Modlin R L, Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol 2005: 125: 1-8.
29. Lysa B, Tartler U, Wolf R et al. Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br J Dermatol 2004: 151: 1150-1159.
30. Bos J D, Meinardi M M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000: 9: 165-169.
31. Imbertson L M, Beaurline J M, Couture A M et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998: 110: 734-739.
32. Hengge U R, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 2004: 30: 1101-1112.
33. Gibson S J, Imbertson L M, Wagner T L et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995: 15: 537-545.
34. Megyeri K, Au W C, Rosztoczy I et al. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol Cell Biol 1995: 15: 2207-2218.
35. Tomai M A, Gibson S J, Imbertson L M et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995: 28: 253-264.
36. Testerman T L, Gerster J F, Imbertson L M et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995: 58: 365-372.
37. Wagner T L, Horton V L, Carlson G L et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 1997: 9: 837-845.
38. Weeks C E, Gibson S J. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994: 14: 81-85.
39. Gorden K B, Gorski K S, Gibson S J et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005: 174: 1259-1268.
40. Kono T, Kondo S, Pastore S et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994: 13: 71-76.
41. Kollisch G, Kalali B N, Voelcker V et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 2005: 114: 531-541.
42. Shortman K, Liu Y J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002: 2: 151-161.
43. Colonna M, Trinchieri G, Liu Y J. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004: 5: 1219-1226.
44. Barchet W, Cella M, Colonna M. Plasmacytoid dendritic cells - virus experts of innate immunity. Semin Immunol 2005: 17: 253-261.
45. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999: 5: 919-923.
46. Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001: 194: 863-869.
47. Nakano H, Yanagita M, Gunn M D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001: 194: 1171-1178.
48. Gibson S J, Lindh J M, Riter T R et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002: 218: 74-86.
49. Diebold S S, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004: 303: 1529-1537.
50. Liu Y J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005: 23: 275-306.
51. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002: 3: 196-200.
52. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004: 173: 3051-3061.
53. Urosevic M, Dummer R, Conrad C et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005: 97: 1143-1153.
54. Burns R P Jr, Ferbel B, Tomai M, Miller R, Gaspari A A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000: 94: 13-23.
55. Suzuki H, Wang B, Shivji G M et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000: 114: 135-141.
56. Gunzer M, Riemann H, Basoglu Y et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005: 106: 2424-2432.
57. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004: 151: 656-662.
58. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004: 50: 722-733.
59. Korman N, Moy R, Ling M et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: Results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005: 141: 467-473.
60. Levy O, Zarember K A, Roy R M, Cywes C, Godowski P J, Wessels M R. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 2004: 173: 4627-4634.
61. Ahonen C L, Gibson S J, Smith R M et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 1999: 197: 62-72.
62. Fogel M, Long J A, Thompson P J, Upham J W. Dendritic cell maturation and IL-12 synthesis induced by the synthetic immune-response modifier S-28463. J Leukoc Biol 2002: 72: 932-938.
63. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005: 6: 769-776.
64. Ahonen C L, Doxsee C L, McGurran S M et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004: 199: 775-784.
65. Wagner T L, Ahonen C L, Couture A M et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999: 191: 10-19.
66. Caron G, Duluc D, Fremaux I et al. Direct stimulation of human T cells via TLR5 and TLR7/8: Flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 2005: 175: 1551-1557.
67. Tousignant J D, Zhao H, Yew N S, Cheng S H, Eastman S J, Scheule R K. DNA sequences in cationic lipid: PDNA-mediated systemic toxicities. Hum Gene Ther 2003: 14: 203-214.
68. Tomai M A, Imbertson L M, Stanczak T L, Tygrett L T, Waldschmidt T J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000: 203: 55-65.
69. Soulas P, Woods A, Jaulhac B et al. Autoantigen, innate immunity, and T cells cooperate to break B cell tolerance during bacterial infection. J Clin Invest 2005: 115: 2257-2267.
70. Bernasconi N L, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002: 298: 2199-2202.
71. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002: 168: 4531-4537.
72. Bishop G A, Ramirez L M, Baccam M, Busch L K, Pederson L K, Tomai M A. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol 2001: 208: 9-17.
73. Bishop G A, Hsing Y, Hostager B S, Jalukar S V, Ramirez L M, Tomai M A. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000: 165: 5552-5557.
74. Bekeredjian-Ding I B, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005: 174: 4043-4050.
75. Vasilakos J P, Smith R M, Gibson S J et al. Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN. Cell Immunol 2000: 204: 64-74.
76. Frotscher B, Anton K, Worm M. Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J Invest Dermatol 2002: 119: 1059-1064.
77. McArthur J C, Brew B J, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005: 4: 543-555.
78. Studahl M. Influenza virus and CNS manifestations. J Clin Virol 2003: 28: 225-232.
79. Zhang Z, Trautmann K, Schluesener H J. Microglia activation in rat spinal cord by systemic injection of TLR3 and TLR7/8 agonists. J Neuroimmunol 2005: 164: 154-160.
80. Schön M P, Wienrich B G, Drewniok C et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004: 122: 1266-1276.
81. Schön M, Bong A B, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003: 95: 1138-1149.
82. Barnetson R S, Satchell A, Zhuang L, Slade H B, Halliday G M. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004: 29: 639-643.
83. Wolf I H, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005: 141: 510-514.
84. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003: 207: 326-328.
85. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003: 139: 1325-1332.
86. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit Rev Immunol 2001: 21: 133-145.
87. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin Immunol 2001: 13: 291-302.
88. Halliday G M, Patel A, Hunt M J, Tefany F J, Barnetson R S. Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. World J Surg 1995: 19: 352-358.
89. Schön M P, Schön M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004: 9: 291-298.